Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation
Senores Pharmaceuticals Ltd · Investor Presentation · 29 Oct 2026, 8:16 pm
Senores Pharmaceuticals Q2 and H1 FY27 Performance Presentation Senores Pharmaceuticals reported consolidated revenue growth of 25% YoY to ₹192.3 Cr in Q2 FY27 and 30% YoY to ₹372.5 Cr in H1 FY27. Regulated markets drove 71% of H1 revenue with ~42% EBITDA margins. Consolidated H1 EBITDA surged 58.2% YoY to ₹111.4 Cr, expanding margins by ~530 bps to 29.9%, while PAT rose 31% YoY to ₹67.0 Cr. Growth was supported by 64 approved ANDAs and forward integration through Zoraya and Amerisyn, targeted to accelerate H2 FY27 performance across US government and B2C channels.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... · 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 · 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 · 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible .... · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding media release · 29 Oct 2026
